Abstract
Hypertension is a major risk factor for morbidity and mortality. Plasma catecholamines are linked to the pathogenesis of hypertension. Pharmacological intervention, including treatment with beta-blockers, reduces cardiovascular mortality and morbidity. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the angiotensin receptor blocker losartan significantly reduced cardiovascular end points compared to the beta-blocker atenolol. Thus, for the first time, one drug was shown to be superior to another in hypertension. The present substudy examined the effects of atenolol vs losartan treatment on plasma catecholamines at rest and during hyperinsulinaemia in a cohort of 86 LIFE patients. Plasma adrenaline increased significantly from placebo treatment at baseline to year 1 of treatment (P<0.0001), and also during hyperinsulinaemia (P<0.0001). Plasma noradrenaline did not change significantly from placebo treatment at baseline to year 1, but increased significantly during hyperinsulinaemia both at baseline and at year 1 (P<0.0001 for both). There were no differences in plasma catecholamines or the relative changes between the two treatment arms at any stage. In a subset of 42 patients examined also at years 2 and 3, these findings were confirmed during long-term treatment. Thus, losartan had an effect on plasma catecholamines comparable to that with the beta-blocker atenolol in patients with hypertension and left ventricular hypertrophy at rest and during hyperinsulinaemia. We find it unlikely that a difference in sympathetic activity explains the outcome benefits of losartan over atenolol in the LIFE study.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Ezzati M et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360.
DeQuattro V, Chan S . Raised plasma-catecholamines in some patients with primary hypertension. Lancet 1972; l: 806–809.
Egan B et al. Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin Invest 1987; 80: 812–817.
Eliasson K, Hjemdahl P, Kahan T . Circulatory and sympatho-adrenal responses to stress in borderline and established hypertension. J Hypertens 1983; 1: 131–139.
Hjemdahl P . Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol 1988; 63 (Suppl 1): 27–31.
Julius S, Schork N, Schork A . Sympathetic hyperactivity in early stages of hypertension: the Ann Arbor J;data set. J Cardiovasc Pharmacol 1988; 12 (Suppl 3): S121–S129.
Kjeldsen SE, Schork NJ, Leren P, Eide IK . Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 1989; 118: 775–781.
Dahlöf B et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.
Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.
ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–1975.
Kjeldsen SE, Westheim AS, Os I . INSIGHT and NORDIL. International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study. Lancet 2000; 356: 1929–1930.
Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Olsen MH et al. Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. J Hypertens 2000; 18: 75–81.
Olsen MH et al. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Blood Press 2000; 9 (2-3): 132–139.
Appel E et al. Determination of plasma catecholamines by means of radioenzymatic labelling and high pressure liquid chromatographic separation. Naunyn Schmiedebergs Arch Pharmacol 1981; 315: 233–239.
Best JD, Halter JB . Release and clearance rates of epinephrine in man: importance of arterial measurements. J Clin Endocrinol Metab 1982; 55: 263–268.
Esler M . Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics. Clin Sci 1982; 62: 247–254.
Gullestad L et al. Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise. Cardiovasc Drugs Ther 1989; 3: 63–71.
Reid IA . Interactions between ANG ll, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763–E778.
Ye S, Zhong H, Duong VN, Campese VM . Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 2002; 39: 1101–1106.
Rodriguez-Garcia JL et al. Changes in plasma norepinephrine and endothelin levels and metabolic profile after AT1-receptor blockade in human hypertension. Am J Cardiol 2000; 85: 1147–1150.
Houghton AR, Harrison M, Cowley AJ . Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. Eur J Heart Fail 1999; 1: 385–393.
Grossman E et al. Hemodynamic and humoral effects of the angiotensin ll antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041–1044.
Worck RH, Ibsen H, Frandsen E, Dige-Petersen H . AT1 receptor blockade and the sympathoadrenal response to insulin-induced hypoglycemia in humans. Am J Physiol 1997; 272: E415–E421.
Rowe JW et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219–225.
Seljeflot I et al. Effect of angiotensin ll receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299–1304.
Moan A et al. The glucose clamp procedure activates the sympathetic nervous system even in the absence of hyperinsulinemia. J Clin Endocrinol Metab 1995; 80: 3151–3154.
Acknowledgements
We acknowledge the technical assistance by Lisa Krause in Ann Arbor, Merete Molvig in Oslo, and Ingrid Emanuel in Copenhagen. We acknowledge Paulette A Lyle for assistance with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by a grant from Merck & Co., Inc., West Point, Pennsylvania, USA.
Rights and permissions
About this article
Cite this article
Fossum, E., Olsen, M., Høieggen, A. et al. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. J Hum Hypertens 18, 375–380 (2004). https://doi.org/10.1038/sj.jhh.1001712
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.jhh.1001712
